Search
Selected Filter
Displaying 11–20 of 252 research results
-
Geographic Atrophy: The Advanced Form of Dry AMD
Geographic atrophy causes significant central vision loss and remains an unmet medical need.
-
FDA Approves Genentech’s Susvimo for Treating Wet AMD
The approach significantly reduces the need for regular ocular injections.
-
Atsena Therapeutics Developing X-Linked Retinoschisis Gene Therapy
The emerging gene therapy is being designed to more safely reach the fovea
-
Foundation Hosts Workshop on USH1B Research and Therapy Development
Emerging dual-vector gene therapies to address current cargo-size limitations were highlighted during the meeting.
-
The emerging treatment targets a specific mutation (c.2991+1655A>G in Intron 26) of the gene CEP290 which causes Leber congenital amaurosis 10 (LCA 10)
-
RD Fund Launches Opus Genetics to Advance Gene Therapies for Inherited Retinal Diseases
First two programs are for Leber congenital amaurosis: LCA5-lebercillin and LCA13-RDH12
-
Foundation Awarded 21 New Grants in FY2021 Totaling More than $14.2 Million
Current research portfolio is comprised of nearly 100 projects at prominent institutions around the world
-
MeiraGTx and Janssen Recruiting for Phase 3 XLRP Gene Therapy Clinical Trial
Visit www.LUMEOSstudy.com for more information about trial
-
Apellis to Seek FDA Approval of its Dry AMD Drug
Known as APL-2, the drug met its primary endpoint in the OAKS clinical trial but not the DERBY trial
-
Optogenetics: Hope for Vision Restoration for Advanced Retinal Diseases
Early, encouraging results from two human studies — trials launched by Bionic Sight and GenSight — are putting optogenetic therapies in the spotlight for patients with advanced vision loss from retinal conditions.
.png)
